Literature DB >> 17639567

Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry.

Aleksanteri Petsalo1, Miia Turpeinen, Ari Tolonen.   

Abstract

Human urinary metabolism of the antidepressant bupropion was studied using liquid chromatography/time-of-flight mass spectrometry (LC/TOFMS) and liquid chromatography/tandem mass spectrometry (LC/MS/MS). A total of 20 metabolites were detected and identified. The phase I metabolism included formation of morpholinohydroxybupropion, threo- and erythrohydrobupropion, aromatic hydroxylation, butyl group hydroxylation with ketone hydrogenation and dihydroxylation. These metabolites were detected either as the free form or as glucuronide and/or sulphate conjugates. In addition also m-chlorohippuric acid was detected. Of the phase I metabolites, a dihydroxylation to the aromatic ring and to the methyl group in the middle of the substrate molecule was reported here for the first time, as well as eight of the glucuronide conjugates (to hydroxy, dihydroxy, hydroxy and hydrogenation metabolites) and three of the sulphate conjugates (to aromatic hydroxy and hydroxy and hydrogenation metabolites). Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639567     DOI: 10.1002/rcm.3117

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  13 in total

1.  Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion.

Authors:  Sarah J Hemauer; Svetlana L Patrikeeva; Xiaoming Wang; Doaa R Abdelrahman; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

2.  Metabolism of bupropion by baboon hepatic and placental microsomes.

Authors:  Xiaoming Wang; Doaa R Abdelrahman; Valentina M Fokina; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Biochem Pharmacol       Date:  2011-05-05       Impact factor: 5.858

3.  Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Authors:  Zeruesenay Desta; Ingrid F Metzger; Nancy Thong; Jessica B L Lu; John T Callaghan; Todd C Skaar; David A Flockhart; Raymond E Galinsky
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.

Authors:  Andy Z X Zhu; Qian Zhou; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-09-03       Impact factor: 3.922

5.  Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.

Authors:  Aaron M Teitelbaum; Alicia M Flaker; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-27       Impact factor: 3.205

6.  Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans.

Authors:  Jennifer E Sager; John R Choiniere; Justine Chang; Alyssa Stephenson-Famy; Wendel L Nelson; Nina Isoherranen
Journal:  ACS Med Chem Lett       Date:  2016-06-17       Impact factor: 4.345

7.  Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.

Authors:  Valentina M Fokina; Meixiang Xu; Erik Rytting; Sherif Z Abdel-Rahman; Holly West; Cheryl Oncken; Shannon M Clark; Mahmoud S Ahmed; Gary D V Hankins; Tatiana N Nanovskaya
Journal:  Drug Metab Dispos       Date:  2016-08-15       Impact factor: 3.922

8.  Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.

Authors:  Neal L Benowitz; Andy Z X Zhu; Rachel F Tyndale; Delia Dempsey; Peyton Jacob
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

9.  Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.

Authors:  Rebecka Coles; Evan D Kharasch
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

10.  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Authors:  Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2016-01-22       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.